BioSpace News Archive

Dr. Xueming Qian will share the company’s latest development and clinical progresses made to the audience and potential investors.

Pharmacists have unique expertise and opportunities to positively influence medication adherence by their patients – including understanding their directions for use, remembering to take medications, and filling their prescriptions regularly.

These inflatable cuffs are designed to be strapped on the upper arm or thigh to practice BFR training as a way to help build muscle and strength.

Company behind “mega” line of home health products debuts upgraded wellness products and features for tech-enabled homes

Dr. Steven A. Everett, President & CEO, will be presenting the Company technology and investment opportunity at the showcases during the following times

Lovelace Biomedical, a non-profit contract research organization which has been specializing in various fields of biomedical research, including performing non-clinical studies in gene therapy, will host a webinar on their history and expertise in the field.

Canavation Product Group, Inc. (“Canavation”) announced today that it has acquired Bio Lab Naturals (“Bio Lab”) including its wholly owned subsidiary Pure Solutions, Inc. Pure Solutions is the manufacturing arm for Bio Lab.

Stryker (NYSE:SYK) announced that it will host a conference call on Tuesday, January 28, 2020 at 4:30 p.m., Eastern Time, to discuss the Company’s operating results for the quarter ended December 31, 2019 and provide an operational update.

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

Neovasc Inc. announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,185,000 series A units and 1,241,490 series B units at a price of US$4.1351 per Series A Unit and US$4.135 per Series B Unit for aggregate gross proceeds to the Company of approximately US$10 million, before deducting placement agent’s fees and estimated expenses of the Offering payable by the Company.